Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer
oleh: Alfredo Tartarone, Vittoria Lapadula, Concetta Di Micco, Gemma Rossi, Carlotta Ottanelli, Andrea Marini, Roberta Giorgione, Katia Ferrari, Martina Catalano, Luca Voltolini, Enrico Mini, Giandomenico Roviello
| Format: | Article |
|---|---|
| Diterbitkan: | Frontiers Media S.A. 2021-05-01 |
Deskripsi
In the last few years the advent of targeted therapies against oncogenic drivers significantly improved the survival of non small cell lung cancer (NSCLC) patients with a favourable toxicity profile. Therefore, genetic testing, including at least EGFR mutations and ALK/ROS1 rearrangements, should be performed in all NSCLC patients (in particular with adenocarcinoma) who received a diagnosis of advanced disease. This review focuses on novel druggable oncogenic drivers, such as MET exon 14 mutations/MET amplification, RET fusions, BRAF V600E mutations, KRAS G12C mutations, NTRK rearrangements, and HER2 alterations.